로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > MHC 클래스 I 복합 맞춤형 서비스

MHC 클래스 I 복합 맞춤형 서비스

MHC 클래스 I 복합 맞춤형 서비스
배경
인간에서 HLA라고도 알려진 MHC I(Major histocompatibility complex class I)은 체내 모든 핵형 세포에서 발현되는 다양한 세포 표면 수용체 세트입니다. 적응 면역 시스템에서 중요한 역할을 합니다. 생체 내에서 MHC I은 온전한 단백질의 항원 펩티드 조각과 결합할 수 있습니다. 펩티드-MHC 복합체는 T 림프구의 항원 특이적 수용체에 의해 인식되며, 인식되면 활성화된 T 세포가 면역 반응에 기여하고 명확한 감염에 도움이 됩니다. 적응 면역에 매우 중요한 고도로 특이적인 T 세포 매개 반응을 허용하는 MHC I 표시 펩티돔. 따라서 펩티드-MHC I 복합체와 TCR 사이의 깊은 관계에 대한 연구는 메커니즘 조사 및 약물 개발에 점점 더 중요해지고 있습니다.
mhc 관련 연구를 더 잘 지원하기 위해, ACROBiosystems는 원핵 재접힘 과정의 불안정성, 잘못된 복잡한 변형 및 기타 문제를 피하기 위해 진핵 단백질 발현 기술 플랫폼과 함께 성숙한 단백질 구조 설계 플랫폼에 의존합니다.이러한 플랫폼을 사용하여 다양한 형광 라벨이 사용 가능한 단량체, 테트라머 형태 모두에서 생물학적 활성이 높은 일련의 천연 MHC 복합체를 성공적으로 개발했습니다.여기에는 NY-ESO-1, WT-1, GP100, GPC 및 기타 많은 대상과 같은 대상이 포함됩니다.뿐만 아니라 고객의 다양한 요구를 충족시키기 위해 고객의 특정 요구 및 용도에 따라 자연스러운 컨버전스가 가능하도록 기술 플랫폼을 활용한 맞춤형 mhc-펩타이드 복합체 개발 서비스도 제공하고 있습니다.

여기를 클릭해서 맞춤형 서비스를 알아보기

서비스 특징

진핵 발현 플랫폼의 진핵 기반 구조

이종이량체의 공동 발현은 보다 자연스러운 형태를 초래합니다.

다양한 종류의 MHCI 및 항원이 있습니다

단량체/테트라머 형태

FITC/PE/APC/Biotin 라벨은 옵션입니다

성숙생체활성확인 플랫폼 : SPR/ELISA/FACS 등

MHC-복합체 사량체
공동 발현 단량체: 비오틴화된 MHC 클래스 I 중쇄 및 β2-마이크로글로불린(β2m)은 HEK293 시스템에서 공동 발현되고 시험관 내에서 정제되어 MHC 클래스 I 단량체(펩티드 없음)를 얻습니다.
짧은 펩타이드 로딩: MHC class I (peptide free) 단량체를 항원성 펩타이드와 공동 배양하여 단량체 MHC class I-펩타이드 복합체를 얻었습니다.
사량체화: 이어서, MHCi 유사 펩티드 복합체 단량체는 형광 염료 표지된 사슬 아비딘을 첨가하여 결찰되었습니다.

MHC-Complex Tetramer

맞춤형 제품 목록
MHC Allele
Human classical MHC class IHuman classical MHC IIMouseMonkey
Antigens

여기를 클릭해서 맞춤형 서비스를 알아보기


Product Data
  • Bioactivity

  • Homogeneity

  • Stability

  • Competitive Data

Cell Binding Activity – FACS, Flow Cytometry

Binding activity of PE-labelled HLA-A*02:01&B2M&NY-ESO-1 tetramers were verified using anti-NY-ESO-1 TCR-293 cells and flow cytometry. Cleanly defined populations bound with MHC tetramers were observed in comparison to negative control proteins.
PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer
Cat. No.: HL1-HP2E5
Cell Binding Activity – FACS, Flow Cytometry

PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-HP2E5) and negative control protein were first diluted in a 1:25 dilution ratio with FACS buffer. Staining was performed using 100 µL of working solution to 5e5 anti-NY-ESO-1 TCR-293 cells. Binding activity was evaluated based on PE signal intensity (QC tested).


PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer
Cat. No.: HL1-HP2E6
Cell Binding Activity – FACS, Flow Cytometry

PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-HP2E6) and negative control protein were first diluted in a 1:25 dilution ratio with FACS buffer. Staining was performed using 100 µL of working solution to 5e5 anti-NY-ESO-1 TCR-293 cells. Binding activity was evaluated based on PE signal intensity (QC tested).


MHC Structure Verification – ELISA

MHC tetramers are structurally evaluated using either NY-ESO-1 specific antibodies or MHC skeleton (W6/32) targeting antibodies. Proper binding curves were observed using both antibodies, ensuring correct and natural MHC structures.
Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein with Anti-NY-ESO-1 antibodies, Human IgG1.
Cat. No.: HL1-H82E6
MHC Structure Verification – ELISA

Immobilized Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).


Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein with Anti-HLA Class I Antibody (W6/32), Human IgG1.
Cat. No.: HL1-H82E6
MHC Structure Verification – ELISA

Immobilized Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-1 ng/mL (Routinely tested).


Antibody Binding Activity – SPR

MHC tetramer binding was evaluated using MHC skeleton (W6/32) targeting antibodies. Proper binding curves were observed using both antibodies, ensuring good specificity and affinity.
Human HLA-A*11:01&B2M&KRASG12D (VVGADGVGK) with Anti-HLA Class I Antibody (W6/32), Human IgG1.
Cat. No.: HLD-H52H4
Antibody Binding Activity – SPR

Anti-HLA class I Antibody, Human IgG1 (W6/32) captured on Protein A Chip can bind Human HLA-A*11:01&B2M&KRASG12D (VVGADGVGK) Complex Protein (Cat. No. HLD-H52H4) with an affinity constant of 1.06 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).


SDS-PAGE & SEC-MALS Evaluations

MHC proteins are evaluated for purity and homogeneity using SDS-PAGE and SEC-MALS. Purity was evaluated to be higher than 90%, with good homogeneity.
Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein
Cat. No.: HL1-H82E6
SDS-PAGE & SEC-MALS Evaluations

The purity of Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) is more than 90% and the molecular weight of this protein is around 45-65 kDa verified by SEC-MALS.

Biotinylated Human HLA-A*02:01&B2M Complex Protein
Cat. No.: HLM-H82W3
SDS-PAGE & SEC-MALS Evaluations

The purity of Biotinylated Human HLA-A*02:01&B2M Complex Protein (Cat. No. HLM-H82W3) is more than 90% and the molecular weight of this protein is around 47-62 kDa verified by SEC-MALS.


HLA Skeleton Stability

By avoiding any prokaryotic transformation processes, the HLA skeleton developed independently by ACROBiosystems adopts a light and heavy-chain natural co-transmutation of human cells to reveal a closer-to-natural structure and has better structural stability.
HLA-A*2402&B2M Complex Protein
Cat. No.: HLM-H82W4
HLA Skeleton Stability

HLA-A*2402&B2M complex protein was verified to be stable after incubation under 37 degrees for 24 hours, and no significant dissociation of HLA-A*2402 and B2M (Cat. No. HLM-H82W4) was observed from HPLC analysis.


MHC-Peptide Complex Stability

Biological Activity of MHC-peptide tetramer complex retains its biological activity and is stable after 48h in 37°C, as well as after 3 freeze-thaw cycles.
Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein
Cat. No.: HL1-H52E8
MHC-Peptide Complex Stability

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (MALS verified) (Cat. No. HL1-H52E8) is stable in undiluted samples at 37℃ for 48 h and freeze-throw cycles are stable without performance reduction.


ACROBiosystems’ independently developed HLA skeleton utilizing non-prokaryotic transformation processes has several advantages over our competitors, including:
Better Sensitivity:  Higher Mean Fluorescent Intensity (MFI) reveals a more intense fluorescent signal for low concentration studies.
Natural Conformation:  HEK293-based expression systems maintain the natural human structure and results in both better structural stability and cell-based binding.
PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC)
Cat No.: HL1-HP2E5
MHC-Peptide Complex Stability

Performance of PE-labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer from ACROBiosystems (Cat. No. HL1-HP2E5) and other brand were evaluated by flow cytometry under the manufacturer’s recommended conditions. ACROBiosystems’ PE-Labeled NY-ESO-1 Tetramer Protein shows 3x higher MFI signal strength than competitor M, revealing much better TCR binding.


PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV)
Cat No.: HL1-HP2E6
MHC-Peptide Complex Stability

Performance of PE-labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer from ACROBiosystems (Cat. No. HL1-HP2E6) and other brand were evaluated by flow cytometry under the manufacturer’s recommended conditions. ACROBiosystems’ PE-Labeled NY-ESO-1 Tetramer Protein shows 2x higher MFI signal strength than competitor M, revealing much better TCR binding.


추천 제품

관련 제품

참고문헌

  • 1.Thomas C, Tampé R. MHC I assembly and peptide editing - chaperones, clients, and molecular plasticity in immunity. Curr Opin Immunol. 2021 Jun;70:48-56. doi: 10.1016/j.coi.2021.02.004. Epub 2021 Mar 6. PMID: 33689959.

  • 2.Becar M, Kasi A. Physiology, MHC Class I. 2021 Sep 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32310482.

ACRO Quality

This web search service is supported by Google Inc.

totop